Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.
Publication
, Conference
Mamdani, H; Clarke, JM; Gu, L; Stinchcombe, T; Crawford, J; Antonia, SJ; Campa, M; Nixon, AB; Sonpavde, GP; Simon, GR; Ready, NE; Patz, EF ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mamdani, H., Clarke, J. M., Gu, L., Stinchcombe, T., Crawford, J., Antonia, S. J., … Patz, E. F. (2024). Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Mamdani, Hirva, Jeffrey Melson Clarke, Lin Gu, Tom Stinchcombe, Jeffrey Crawford, Scott Joseph Antonia, Michael Campa, et al. “Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Mamdani H, Clarke JM, Gu L, Stinchcombe T, Crawford J, Antonia SJ, et al. Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Mamdani, Hirva, et al. “Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Mamdani H, Clarke JM, Gu L, Stinchcombe T, Crawford J, Antonia SJ, Campa M, Nixon AB, Sonpavde GP, Simon GR, Ready NE, Herndon JEII, Patz EF. Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study. JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences